| Literature DB >> 27350323 |
Dandan Liu1, Jinyu Li2, Hao Pan3, Fengwei He1, Zhidong Liu4, Qingyin Wu1, Chunping Bai1, Shihui Yu2, Xinggang Yang2.
Abstract
The transient precorneal retention time and low penetration capacity into intraocular tissues are the key obstacles that hinder the ophthalmic drug delivery of many therapeutic compounds, especially for drugs with poor solubility and permeability. To break the stalemate, N-acetyl-L-cysteine functionalized chitosan copolymer (CS-NAC), which exhibit marked bioadhesion and permeation enhancing effect, was synthesized. The curcumin encapsulated NLC (CUR-NLC) was produced and optimized followed by surface absorption of CS-NAC. After coating, changed particle size from 50.76 ± 2.21 nm to 88.64 ± 1.25 nm and reversed zeta potential from -20.38 ± 0.39 mV to 22.51 ± 0.34 mV was observed. The in vitro CUR release from NLC was slower than that of CUR-NLC and chitosan hydrochlorides (CH) coated NLC due to the inter and/or intramolecular disulfide formation of thiomers on the surface of nanocarriers. The modification also significantly enhanced transcorneal penetration compared with CH-NLC and the uncoated ones. The effect on bioadhesion and precorneal retention were evaluated by in vivo imaging technique and ocular pharmacokinetics studies revealing that the clearance of the formulations was significantly delayed in the presence of CS-NAC and the effect was positively related to the degree of thiolation. In summary, CS-NAC-NLC presented a series of notable advantages for ophthalmic drug application.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27350323 PMCID: PMC4923878 DOI: 10.1038/srep28796
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(A) Synthetic scheme of CS-NAC copolymer. (B) 1H NMR spectrum of CS and CS-NAC copolymer. (C) PXRD patterns of CS and CS-NAC.
The content of thiol groups attached to the CS (mean ± S.D., n = 3).
| Copolymer | NAC:CS (molar ratio) | Free thiol groups (μmol/g) | Disulfide content (μmol/g) | Total thiol groups (μmol/g) |
|---|---|---|---|---|
| CS-NACH | 4:1 | 496.7 ± 17.1 | 103.5 ± 19.4 | 600.2 ± 28.8 |
| CS-NACM | 2:1 | 320.3 ± 25.1 | 69.6 ± 5.3 | 389.9 ± 22.5 |
| CS-NACL | 1:1 | 200.3 ± 17.3 | 43.6 ± 16.9 | 243.9 ± 15.4 |
Factor levels and observed responses for central composite design.
| No. | Levels of independent factors | Responses | |||||
|---|---|---|---|---|---|---|---|
| X1 (mg) | X2 | X3 (mg) | Y1(nm) | Y2 | Y3(mV) | Y4(%) | |
| 1 | 150 | 0.50 | 127 | 43.37 ± 0.87 | 0.18 ± 0.02 | −14.4 ± 0.32 | 90.87 ± 1.23 |
| 2 | 170 | 0.32 | 90 | 99.74 ± 2.32 | 0.13 ± 0.01 | −20.4 ± 0.56 | 84.11 ± 0.78 |
| 3 | 170 | 0.68 | 164 | 41.61 ± 1.78 | 0.19 ± 0.00 | −8.01 ± 0.21 | 88.79 ± 2.03 |
| 4 | 170 | 0.68 | 90 | 49.59 ± 2.78 | 0.14 ± 0.01 | −22.90 ± 0.45 | 88.96 ± 1.15 |
| 5 | 170 | 0.32 | 164 | 52.30 ± 3.48 | 0.22 ± 0.03 | −17.64 ± 0.67 | 83.21 ± 1.59 |
| 6 | 200 | 0.50 | 190 | 39.53 ± 2.54 | 0.19 ± 0.02 | −12.20 ± 0.28 | 97.19 ± 3.03 |
| 7 | 200 | 0.80 | 127 | 57.77 ± 1.56 | 0.17 ± 0.01 | −16.93 ± 0.33 | 83.93 ± 1.45 |
| 8 | 200 | 0.50 | 127 | 56.56 ± 3.87 | 0.09 ± 0.01 | −13.62 ± 0.71 | 87.79 ± 0.54 |
| 9 | 200 | 0.50 | 64 | 110.14 ± 5.02 | 0.17 ± 0.03 | −22.76 ± 0.68 | 88.57 ± 1.02 |
| 10 | 200 | 0.50 | 127 | 57.87 ± 1.69 | 0.10 ± 0.00 | −13.18 ± 0.15 | 88.31 ± 0.44 |
| 11 | 200 | 0.20 | 127 | 157.23 ± 6.18 | 0.21 ± 0.01 | −20.63 ± 0.37 | 48.9 ± 1.67 |
| 12 | 200 | 0.50 | 127 | 52.36 ± 1.34 | 0.09 ± 0.02 | −13.51 ± 0.43 | 87.74 ± 0.60 |
| 13 | 200 | 0.50 | 127 | 58.47 ± 2.77 | 0.10 ± 0.01 | −12.93 ± 0.28 | 85.21 ± 0.39 |
| 14 | 200 | 0.50 | 127 | 53.28 ± 0.99 | 0.09 ± 0.03 | −13.47 ± 0.22 | 85.44 ± 1.59 |
| 15 | 200 | 0.50 | 127 | 49.74 ± 3.11 | 0.10 ± 0.02 | −14.15 ± 0.41 | 88.93 ± 1.65 |
| 16 | 230 | 0.68 | 164 | 46.96 ± 2.55 | 0.14 ± 0.03 | −13.43 ± 0.18 | 85.20 ± 0.74 |
| 17 | 230 | 0.32 | 90 | 192.52 ± 4.03 | 0.21 ± 0.01 | −12.12 ± 0.35 | 38.93 ± 0.70 |
| 18 | 230 | 0.32 | 164 | 91.65 ± 3.87 | 0.21 ± 0.04 | −16.75 ± 0.17 | 65.87 ± 0.83 |
| 19 | 230 | 0.68 | 90 | 91.97 ± 1.21 | 0.15 ± 0.02 | −21.21 ± 0.09 | 59.70 ± 1.22 |
| 20 | 250 | 0.50 | 127 | 89.03 ± 0.85 | 0.18 ± 0.01 | −8.88 ± 0.06 | 53.89 ± 0.99 |
Factors—X1: the total mass of medium chain triglyceride (MCT) and glyceryl monostearate (GMS); X2: GMS/MCT mass ratio; and X3: the amount of Solutol HS15. Responses—Y1: the mean particle size (PS); Y2: polydispersity index (PI); Y3: zeta potential (ZP); and Y4: entrapment efficiency (EE).
Figure 2Three-dimensional (3D) response surface plots showing the effect of the variables on the responses.
Physicochemical characterization of NLCs (mean ± S.D., n = 3).
| Responses | NLC | CH-NLC | CS-NACH-NLC | CS-NACM-NLC | CS-NACL-NLC |
|---|---|---|---|---|---|
| PS (nm) | 50.76 ± 2.21 | 93.04 ± 1.87 | 88.64 ± 1.25 | 71.52 ± 1.43 | 70.25 ± 1.81 |
| PI | 0.11 ± 0.02 | 0.28 ± 0.05 | 0.17 ± 0.01 | 0.16 ± 0.02 | 0.16 ± 0.02 |
| ZP (mV) | −20.38 ± 0.39 | 30.23 ± 0.25 | 22.51 ± 0.34 | 14.62 ± 0.64 | 11.73 ± 0.27 |
| EE (%) | 90.06 ± 1.82 | 90.49 ± 3.21 | 96.62 ± 3.13 | 95.33 ± 2.25 | 95.02 ± 0.81 |
aStatistically significant compared with the NLC (p < 0.05).
bStatistically significant compared with the CH-NLC (p < 0.05).
cStatistically significant compared with the CS-NACH-NLC (p < 0.05).
Figure 3(A) Schematic representation of formation of CS-NAC-NLC. (B) TEM images of (a) CUR-NLC and (b) CS-NACH coated CUR-NLC. (C) DSC profiles of bulk CUR, physical mixture, CUR-NLC, and CS-NACH-NLC. (D) PXRD diffractions of bulk CUR, physical mixture, CUR-NLC, and CS-NACH-NLC.
Figure 4(A) In vitro cumulative release profiles of CUR preparations. (B) Ex vivo cornea penetration curves of CUR preparations. (C) Real-time in vivo fluorescence imaging of CUR preparations.
Permeation parameters of CUR formulations through the excised corneas (mean ± S.D., n = 3).
| Eye drops | NLC | CH-NLC | CS-NACL-NLC | CS-NACM-NLC | CS-NACH-NLC | |
|---|---|---|---|---|---|---|
| Jss (0–60 min) (×10−4 μg·cm−2·s−1) | 3.20 ± 0.35 | 10.13 ± 0.21 | 15.3 ± 0.33 | 46.06 ± 0.15 | 57.65 ± 0.61 | 65.56 ± 0.64 |
| Jss (60–360 min) (×10−4 μg·cm−2·s−1) | 1.66 ± 0.07 | 3.30 ± 0.06 | 5.12 ± 0.03 | 14.98 ± 0.07 | 20.05 ± 0.06 | 21.4 ± 0.34 |
| Papp (0–60 min) (×10−6 cm·s−1) | 0.54 ± 0.04 | 1.69 ± 0.09 | 2.55 ± 0.02 | 7.67 ± 0.11 | 8.71 ± 0.06 | 10.90 ± 0.21 |
| Papp (60–360 min) (×10−6 cm·s−1) | 0.19 ± 0.01 | 0.56 ± 0.02 | 0.85 ± 0.02 | 2.99 ± 0.12 | 3.35 ± 0.10 | 3.57 ± 0.05 |
| R2(0–60 min) | 0.9954 ± 0.0017 | 0.9994 ± 0.0005 | 0.9998 ± 0.0004 | 0.9986 ± 0.0012 | 1.0000 ± 0.0003 | 0.9998 ± 0.0002 |
| R2(60–360 min) | 0.9981 ± 0.0023 | 0.9997 ± 0.0008 | 0.9953 ± 0.0001 | 1.0000 ± 0.0002 | 0.9999 ± 0.0013 | 0.9999 ± 0.0011 |
aStatistically significant compared with the eye drops (p < 0.05).
bStatistically significant compared with the NLC (p < 0.05).
cStatistically significant compared with the CH-NLC (p < 0.05).
dStatistically significant compared with the CS-NACL-NLC (p < 0.05).
eStatistically significant compared with the CS-NACM-NLC (p < 0.05).
Figure 5The concentration–time curves of CUR in rabbit tears following topical administration of CUR eye drops and NLCs (mean ± S.D., n = 6).
Pharmacokinetic parameters of CUR eye drops and NLCs in rabbit tears (mean ± S.D., n = 6).
| Group | Cmax (μg/mL) | AUC(0-∞) (μg/mL/min) | MRT(0-∞)(min) |
|---|---|---|---|
| Eye drops | 16.58 ± 1.98 | 606.95 ± 25.23 | 48.42 ± 10.20 |
| NLC | 64.36 ± 2.25 | 3622.32 ± 59.51 | 61.73 ± 1.79 |
| CH-NLC | 87.62 ± 2.68 | 7435.69 ± 379.39 | 106.21 ± 16.51 |
| CS-NACH-NLC | 147.36 ± 4.93 | 18134.61 ± 863.72 | 141.14 ± 15.45 |
aStatistically significant compared with the eye drops (p < 0.05).
bStatistically significant compared with the NLC (p < 0.05).
cStatistically significant compared with the CH-NLC (p < 0.05).